Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
By voting you contribute to allowing management to attain a quorum. Over half of the shares must be voted by the individual or by proxy. By returning your ballot or granting your proxy, you allow management to reach the goal of getting over half of the shares represented. That is necessary for any proposition to be considered.
For example, if 50.1% of the shares are returned or voted, then only 50.1% of those returned are needed to vote for the measure for it to pass. In this scenario, less than 25.1% of the shareholders can pass a measure.
By withholding your vote and/or proxy, you are sending a message to management and are also helping to prevent the passage. By Voting against the measure, you are actually helping the measure pass.
I don't think voting against the measure is doing anything except helping to pass it. You can revoke your proxy and send an even stronger message.
Treating herpes in infants was the primary target of the Phanuel Pursuits initial project in India. Pre-natal and neo-natal herpes are the pirmary cause for blindness in newborns. Google "herpes, India, neo-natal" and you will be able to learn as much as you'd like about the problem. I still do not understand why CYGX chose to get into a law suit over the license there instead of getting into the testing. Every excuse I've heard here sounds totally impotent and lame. I just don't believe what has been floated around ... doesn't make any sense.
As for War of the Worlds, I thought the writing was at best third class, the plot totally transparent and the acting below par. The SFX and EFX were good to great. Overall my impression was that it made "Mars Attacks" look like a literary and movie masterpiece. The little girl did have some scenes in which she was a carbon copy of every other little girl that age ... LOLOL.
If you, a shareholder, had three (or more) questions that you could ask CYGX management, what would they be? Would they relate to progress with the various projects, or would they concern the manner in which funds have been raised and spent, or would they relate to the legal matters which have risen, or what ..... ?
Is there anything about past business practices that bother you as a shareholder and you would like to have an explanation?
Let's get a list together. Management reads this board and would surely welcome the opportunity to address the questions of the shareholders. If not, there are other ways to get questions answered .... hmmmmmmmmmmm
Captain, you are a true hero ... as an Admiral, I hereby award you the Order of Shareholder Heroes Medal ....
Hogger, Admiral, Republic of Texas Navy
Paul, are you sure that CYGX has not spent any money buying "paid interviews" for publication on the internet? I'd appreciate just a yes or no answer for the record. Do you honestly think Jett would actively assist in diluting his equity by 15%?
Doctor Rick has been a geat asset to CYGX over the years and it just looks like he has had enough of this latest 'greed display." When it comes to research and DD, he has a record that most of us would envy ... (of course, he is not as handsome as me). LOLOL Rick has saved more than few lives from a terrible killer ... when he talks, I listen.
I'm suggesting that this whole share giveaway is the wrong thing at the wrong time and the easiest way to defeat it is to withhold a quorum by not returning a vote or a proxy. If we are going to spend equity, then let's at least get something for it.
BTW, are you perchance a Jesuit priest ... answering a question with a question.
Remember ... arbeit mact frei (sp) ... or share giveaway helps shareholders.
Wonderful HC, and just what is this good news, and when is it going to be passed along to all of us? Have we got new financing at bargain rates instead of existing by PPOs that are for a third of the sell price? Have our legal problems ceased to exist? (Maybe those 18MM shares could make the problems go away.)
As for management wanting shares NOW ... that sounds just like the cavalier attitude we have experienced in the past. If everything has such a rosy future, then why isn't there a little patience ... is it because they know something we don't know ... is it good or is it bad ... are a couple of our fearless leaders fixing to jump ship .... hmmmmmmmmmmmmm.
Come on HC, explain again how diluting our equity by 15% is good for us. Please.
Don't forget that the "compensation committee" can do anything they want to do. They can make any determination and change that suits their fancy. Once the 18MM shares are authorized, there is nothing to prevent them being idssued for any price to anyone tha this "committee" decides is deserving. They are not bound by anything in the proposal.
DON'T GIVE YOUR PROXY. DON'T VOTE>
We have had several reports of folks being contacted by CYGX and being asked to return their proxy. Seems that they are not getting the same response they have received in the past when folks just almost automatically returned the proxy.
Nobody is REQUIRED to return anything. If you are told that you must return it, please drop a note to cygxproxy@sbcglobal.net and outline the circumstances.
Second, failure to return a proxy and the lack of a quorum will NOT cause CYGX to cease business, or even to be unable to transact anything. That is total BS. If told that by anyone, don't buy it.
Third, there has been nothing whatsoever posted that supports this latest share giveaway. Every feeble attempt at hyping it has been totally refuted by logic and truth.
DO NOT RETURN YOUR PROXY. DO NOT VOTE AGAINST (OR FOR)ANYTHING.
Shareholders who oppose the currently porposed share giveaway to a select few in management are enouraged to NOT send in their proxies. The best chance to defeat this proposal is to prevent the attaining of a quorum.
Remember, voting against the proposal will in effect be a vote for it. If 50.1% of the shares are represented, then it only takes 25.1% of the total shares to pass it, so please just don't give anyone your proxy and refrain from voting.
Can someone give us a report on the shareholders meeting? Was there any news?
Certainly no offense taken ... in fact, even LO, RC, etal have used an old technique of mis(dis)information to actually lend an air of credibility to their posts. Everything they say is not right, nor is everything they say wrong. By mixing in just enough truth to prevent obvious prevarication, they are able to project a degree of credibility.
Of course, that same tactic is used daily by their opposite numbers ... LOL. Oh well, off to the moon .....
Good to be receiving more responses at cygxproxy@sbcglobal.net. I don't think some members of management realize just what a firestorm they have unleashed by not withdrawing the share giveaway proposal. Lots of unhappy campers (uh, pardon me happycamper) and the tone is sometimes rather .... uh, let us say, kinda ominous.
Paul, if you will look on page 8 of the Form 10K-SB, you'll find Ewell.
Your argument makes about as much sense as the silly spat you had with Arnold earlier over the degree to which CYGX Management got their behinds booted in the Waldroff suit. I have nothing to wriggle out of. I have posted your words and added my commentary.
Of course you didn't say "and result in an additional 15% dilution in shareholder value, therefore we should all withhold our votes and proxies." I added that as commentary. Because my post references you total previous post, there is no conflict. If you doubt that, go check the NBC Stylebook.
You did say, "the bottom line is a quorum will surely hurt our company and the progess of the science.."
I agree ... we do not need a quorum.
BTW, in both your and Paulnesses posts, there is frequently a plethora of punctuation errors or an absence of punctuation. How about getting some assistance in composing your posts so that we will understand what you are attempting to say when you say something. Who gave you the verbiage for you post 20233? Sounds to me like you got instructions from someone in management and may have not interpreted it correctly.
No, you hold it, gdepc ... here is exactly what you posted and the link to it ... is it or is it not your post?
the bottom line is a quorum will surely hurt our company and the progess of the science.
http://www.investorshub.com/boards/read_msg.asp?message_id=6819889
I agree absolutely and that is why we are encouraging shareholders to withhold their votes and proxies so that a quorum will not be reached.
If there is a quorum of 50.1% and 25.1% vote for the proposals, they will pass. If only 49.99% of the shares are represented by proxy or by vote, then there will not be a quorum and these proposals will have to be resubmitted and maybe next time management will realize that their share-giveaway is not going to fly.
As you say, a quorum will hurt the company and result in an additional 15% dilution in shareholder value, therefore we should all withhold our votes and proxies.
Good to see that you now oppose these giveaways and want to insure that there is no quorum for the SHM.
That's not correct. You left out proposition three (3). The approval of the 2005 Stock Option Plan of the Company. Any particular reason for the slip?
We can function as usual without ratification of either the two nominees for the BOD or the auditors. Failure to pass these will NOT throw any monkey wrench into the operations.
And your statement shown hereinafter is correct (emphasis added):
the bottom line is a quorum will surely hurt our company and the progess of the science.
Okay. I realize that your posting came directly from the court papers and that the posting of the opposing views came from an agency that cygx has paid to put a favorable spin on everything they send out.
The proxy war is indeed going to be a close call due to the large amount of stock held by a very few, but it is very winable. Shareholders representing millions of shares have indicated that they are opposed to the proposal and are going to withhold their proxies and ballots.
A vote AGAINST the proposal could be a vote FOR it if it helps to attain the quorum necessary ... then as few as 25.1% of the shares could pass the measure. I expect a telephone campaign to start at anytime. I believe that management has declined to provide a shareholders list to those who oppose the proposal.
Arnold, I've lost the link to the AVGI website. Do you have it? Could you post it?
AS for the instant disagreement, you are right that CYGX lost the suit they filed and that Waldroff/AVGI won their countersuit only in part. You are correct in surmising that the entire affair was a waste of time, energy, talent and money.
It is interesting that some on this board have to split hairs and debate semantics in lieu of just stating facts.
Also, it is important that all of us opposed to the latest 18MM share giveaway refrain from returning our proxies in order to prevent attaining a quorum. Those 18MM shares could go a long way to settling the problems that management is now facing instead of enriching management for getting us into these messes.
Probably not ... of course, they were worth almost $3.00 a share back then.
Yup, I was just at the transfer company ... great excuse to visit Las Vegas and Reno. Any shareholders except Sasha in those areas? We need to have a party (or at least the buffet) at Bellagio.
HC, I can remember saying that on several occassions ....
They're real and they're spectacular.
Of course they didn't come from CYGX ... LOLOL
Actually we have several alternatives available, but none of them offer the economic incentives to bring them to mass distribution. For instance, there are both the hydrogen and LNG fueled engines. And then there are electric powered engines. Electricity could be generated far more economically using nuclear production, but we all know how that would set with the Hollywood crowd ... LOLOL. I've noticed many LPG buses in China and even here in Houston. We have abundent supplies of gas available, but getting it from the hole to the pump is a big time problem.
Wonderful!!! Do I read this correct? Are you saying that we are going to see $40.00 pershare? Can you give us the date upon which this will occur? Can you promise that this will be done without a reverse split?
yea a guy with 25,000 share will be upset at 40 dollars a share
Holycow, please, please tell me how diluting the shares a further 15% and giving them to a select few is going to benefit shareholders? The only way you are going to benefit is if you are one of those select few. How many shares are you going to get out of this?
I support their proposal, among other reasons, because I believe that I will benefit.
You are 100% correct, Rick. Voting NO is really the same as voting FOR the plan.
And as we approach the SHM, there will no doubt be a concerted telephone campaign to solicit proxies. We have pledges from several million shares promising not to give anyone a proxy.
Even with the proxy withholding campaign, there is still a pretty good chance that this giveaway will pass, but it is our only chance to defeat it, short of legal action. The latter costs money and takes alot of time.
I had really hoped that management would place shareholder interest ahead of their own self interests and would have withdrawn this proposal, but ........
DO NOT VOTE ... DO NOT SEND IN YOUR PROXY ... If you vote, you will be contributing to attaining a quorum. If you withhold your vote, it is better than a NO vote because it reduces the possibility of a vote being legitimate.
You actually have more leverage by withholding the vote.
Example: If 51% of the stock is voted and 26% vote for the option giveaway and 25% vote against it, it will pass. If only 49.99% of the eligible shares are voted, it will not pass, no matter what the percentages are.
Normally management has had to get on the phone to get enough people to send in their proxies to reach a quorum.
PaulNESS, if your feelings are correct, then it would be criminal. You have implied that Management would purposefully keep the price of stock down so they could benefit from the options. Are you crazy? People would go to jail for that kind of behavior. And anyway, with the proposal that is being presented, the so-called compensation committee can set the terms at any level they desire.
You need to engage your brain before allowing your fingers to make such felonious accusations. Are you actually a closet basher?
Also this new PR sounds like the tip of the iceberg, and I get the feeling that big news is being held back until after the share holders meeting .
And why pay more for stock options.
The exercise price of each incentive stock option shall not be less than 100% of the Fair Market Value of the underlying shares of Common Stock on the date of the grant.
Sorry about that Big B ... guess I need these glasses reground ... lolol
Here is some GOOD news ...
CytoGenix Announces Testing of Synthetic DNA Vaccine Against Smallpox
HOUSTON
CytoGenix, Inc., Houston
Juan Ferreira, 800-677-5707
CytoGenix, Inc. (OTCBB:CYGX) announced that it has entered into an agreement with the University of Pennsylvania for animal studies using the company's proprietary synDNA technology to test a DNA vaccine against small pox.
Dr. David B. Weiner, Associate Professor, University of Pennsylvania Medical School, Department of Pathology and Laboratory Medicine, a leading expert in DNA vaccines, will conduct these proof-of-concept studies to determine the immunological activity of the synthetic DNA vaccine compared to a plasmid DNA vaccine.
Smallpox has been eradicated by inoculation programs since 1949 in the U.S. and since 1977 worldwide when the last case was reported in Somalia. Recent threats to national security, however, have caused the Centers for Disease Control and Prevention (CDC) to include the smallpox-causing variola virus as a "Category A" agent (highly dangerous) in the U.S. government's list of bioterrorism biological agents.
The CDC reports in its web site, www.bt.cdc.gov/agent/smallpox, "Because smallpox was wiped out many years ago, a case of smallpox today would be the result of an intentional act. A single confirmed case of smallpox would be considered an emergency." The CDC and other government agencies have plans in place to counter an outbreak of smallpox.
Dr. Weiner comments, "For the past fifteen years, we have worked to bring DNA vaccines into the public health mainstream. One of the chief impediments has been the high cost of pure clinical grade DNA. We are eager to conduct these experiments to determine if vaccines made by this method are as effective or more effective than current DNA vaccines."
Dr. Malcolm Skolnick, CytoGenix President and CEO commented, "We believe that there is an opportunity to develop a smallpox DNA vaccine that will be safer and more effective than the live cowpox vaccine currently available. This important scientific collaboration with Dr. Weiner, a pioneer in this field, demonstrates our strong commitment to advancing DNA vaccine technology to the forefront of clinical use."
CytoGenix, Inc. is a Houston-based biopharmaceutical company that develops and markets innovative products and services based on its proprietary ssDNA expression technology. The company has developed a breakthrough synthetic process for large-scale production of high purity DNA at a fraction of the cost of traditional fermentation methods. CytoGenix currently has one issued U.S. patent and 40 international or U.S. pending patent applications claiming methods and materials in connection with this platform technology.
SAFE HARBOR: Except for statements of historical fact, the statements in this press release are forward-looking. Such statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include, but are not limited to, general economic conditions, risks associated with the acceptance of new products, competition, and other factors more fully detailed in the company's filings with the Securities and Exchange Commission.
Additional information about CytoGenix and its technology can be found on the website at www.cytogenix.com.
Not really ... I think all of us have sold at least a little here and there ... SuperChick and I have sold some in the past, but still have stock in the six digit range. I've never asked the others how much (or if) they sold any. Never thought it was my business.
hogger do you know the answer to that question
gdepc
Paul-NESS, I guess you are more than willing to give up 15% OF YOUR EQUITY AND MY EQUITY AND ALL THE OTHER SHAREHOLDERS EQUITY just so a few under performers can become even weathier. My God, they have already become multimillionaires and still have not got anything to market or even to advanced testing.
Oh well, I suppose that as long as they are not Asian you have no problems with whatever they do to us shareholders.
This is pretty self explanatory. This in and of itself jusitfies withholding our proxy power in order to defeat this additional giveaway. Everyone should read the filing very carefully and look at the figures concerning who has already been given shares.
3.1. Terms and Conditions. The terms and conditions of Options granted under this Article may differ from one another as the Committee shall, in its discretion, determine, as long as all Options granted under this Article satisfy the requirements of this Article.
You may have a very good point there. If management would issue a press release that said that they were not going to submit their share giveaway and STRONGLY refute the rumors of a reverse split, the PPS should stabilize. Now we have an opportunity to see where management really stands when it comes to 'having the shareholders interest at heart.'
Happy, all this BS about the scheme being a money raiser for the corporation is just that ... total BS. It is a classic example of mis(dis)information. It may ring true to a bunch of lollipop licking Pre-K's but the current propoganda campaign is simply silly.
It needs to be withdrawn for the benefit of the shareholders.
We authorized additional shares that can be used to raise money. LW has a small corps of promoters who sell blocks of shares for compensation, and they have been well compensated. Maybe what we need is a short course in the manner in which these have been conducted in the past with emphasis on what was raised, by whom and what the cost in share dilution has been. All anyone has to do is review the filings with the SEC.
I have had enough of this nonsense for a while ... think I'll go out and buy a new Ham Radio. 73 QRS
Paul-ness, if there is a hint of McCarthyism on this board, you must be named Cohen.
Do you recognize an olive branch when you see it??????
*
*
*
*
*
*
*
*
*
*
*
*
http://www.investorshub.com/boards/read_msg.asp?message_id=6670222
If you knew even half as much about the events of history as you need to know, you would not want this to become an all-out conflict.
No, I won't provide them the funds.
Now, if the beneficiaries of this giveaway are going to fund this research and development effort, why have they not taken advantage of the current PPO and bought twice the shares.
Please do not insult the members of this thread with all of this BS about this being a fund raising maneuver. That is not the truth.
If the beneficiaries REALLY want the additional wealth, they can obtain it by devoting the energy, expertise and effort necessary to bring about an increase in the PPS.
Yes CD, we are all stockholders and I have yet to speak with anyone who wants to see the PPS go down. The problem is that there are those who would deify some of the personalities involved and wish we would all just become Nicolas Chauvins. Remember, that even with little Nick's worship, Napolean still fell.
Our backshop is fabulous. Yin, Harylin and the team are dedicated, intelligent, innovative and simply brilliant. Many (with me at the forefront) still believe they will be represented on the stage at Helsinki someday.
Some of our Chauvinists have gone to such extremes that they have managed to push a lot of the old supporters into positions that we feel we must fight back and that is escalating into a bad situation.
Management is not helping. They have introduced a very controversial proposal and it has raised the ire of many of us. Just like some of the other lost battles fought by CYGX management that could have been averted, instead of defusing this time-bomb, management is taking a path that could result in victory only for the hired legal counsel.
If management truly had the best interests of the corporation and the shareholders at heart, they could choose the face saving tactic of withdrawing the proposal and getting on with business, opting to increase their wealth via increasing the value of the corporation.
I expect the hypsters to jump all over me, but that's okay if we can do our own EOD work and stop the explosion that is developing.
I beg management to withdraw their proposal and place the interests of the shareholders ahead of their own desires.
From my post to you:
Are you sure you want to get into a peeing match concerning the ebbs and flows of fortune ... and the underlying reasons for those ebbs and flows? BTW, what have you heard about ISIS lately? Whatever happened to our association with them? Any idea why we have not brought the anti-ICAM to market?
BTW, what did we call it before we decided to call it the anti-ICAM?????????
ISIS has half the shares issued that we have issued. Do you think that has any relationship to the ability of the CFO's to bring in investors?
Here is an interesting PR from ISIS:
Multiple Second-Generation Antisense Drugs Show Potential as New Treatments for Diabetes and Metabolic Disease
Isis Pharmaceuticals and Partners Present Preclinical Research From Broad Antisense Drug Discovery Programs Targeting Metabolic Disease at ADA CARLSBAD, Calif. - PRNewswire-FirstCall - June 13
CARLSBAD, Calif., June 13 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (NASDAQ:ISIS) announced today results from fourteen preclinical studies demonstrating potent, selective antisense inhibitors of gene targets, directly associated with therapeutic potential in a variety of preclinical models of metabolic diseases, including diabetes, non-alcoholic fatty liver disease (NASH) and metabolic syndrome. Findings from the studies were presented by Isis and several collaborators this week during the American Diabetes Association's (ADA) 65th Scientific Sessions in San Diego.
"Data presented this week demonstrate the strong potential of second-generation antisense drugs for metabolic disease. The data show the specificity, efficiency and versatility of second-generation antisense oligonucleotides to rapidly validate novel targets in vivo. This unique advantage of antisense allows us to select the best targets and drugs for drug development. Furthermore, since several of these molecular targets (such as phosphatases and transcription factors) are difficult to inhibit selectively with small molecules, we have a unique drug development opportunity to advance antisense drugs as innovative treatments for metabolic disorders," said C. Frank Bennett, Ph.D., Vice President, Antisense Research at Isis Pharmaceuticals.
This sentiment was echoed by two internationally recognized diabetes experts and Isis collaborators, Dr. Gerald Shulman from Yale University and Dr. Luciano Rossetti from the Albert Einstein College of Medicine, Bronx, New York. "Using Isis' potent antisense inhibitors, we were able to investigate the role of several molecular targets in animal models of diabetes and we identified a critical target that results in the inability of insulin to inhibit excessive glucose release by the liver in obese and insulin resistant rodents," said Dr. Luciano Rossetti, M.D., Professor of Medicine and Molecular Pharmacology and Director, Diabetes Research Center, Albert Einstein College of Medicine, Bronx, NY. "The Isis antisense inhibitors reduced the expression of this gene in the liver and completely restored normal hepatic insulin action."
"Over the past year, we have evaluated over a dozen of Isis' second-generation antisense oligonucleotides designed to target a variety of genes. Through these efforts we have identified several exciting targets, the inhibition of which prevents the development of fatty liver and fat induced insulin-resistance," said Dr. Gerald Shulman, M.D., Ph.D., Professor of Internal Medicine and Cellular and Molecular Physiology, Yale University School of Medicine. "Antisense inhibitors against these targets have great therapeutic potential for type 2 diabetes, obesity and fatty liver disease."
Key Presentations at the ADA:
Targeting Enzymes Involved in Intermediary Lipid Metabolism
In several presentations, optimized antisense inhibitors against key genes involved in intermediary lipid metabolism were evaluated in obese and diabetic animals that had a fatty liver and were insulin resistant. Inhibition of several genes, such as stearoyl-CoA desaturase 1 (SCD-1), acetyl-CoA carboxylases 1 (ACC1) and diacylglycerol acyltransferase 2 (DGAT2) resulted in decreased fat synthesis, increased fat oxidation (burning) and a clearing of fat in the liver. Since antisense oligonucleotides cause specific reduction of these enzymes in the liver and fat, side effects associated with antagonism of these enzymes in other key tissues such as the pancreas and brain were not observed. DGAT2, an enzyme involved in fat synthesis, emerged as one of the most promising targets for future antisense drug development.
Discovery of Novel Phosphatases as Drug Targets for Type 2 Diabetes
Using second-generation antisense oligonucleotides, Isis scientists evaluated more than twenty protein tyrosine phosphatases (PTPases) in animal models of diabetes and obesity. PTPases negatively regulate various cell signaling pathways, including pathways that mediate insulin action. However, traditional small molecule approaches to inhibit phosphatase targets are severely limited due to their lack of specificity. In contrast, specific targeting of phosphatases with antisense technology is a very effective approach to inhibit these targets very selectively. Data were presented demonstrating marked glucose lowering effects of specific antisense oligonucleotides that reduced hepatic expression of several novel phosphatases. Further, reduction of the expression of some of these phosphatases in the liver improved signaling via the insulin receptor and important post-receptor insulin-signaling enzymes. These phosphatases are distinct from protein tyrosine phosphatase-1 (PTP-1B), for which Isis has an antisense drug in Phase 2 clinical trials.
Additional presentations demonstrated glucose lowering effects and improvements in insulin sensitivity in animal models after reduction of hepatic expression of two transcription factors, Foxo1 (also known as Forkhead) and Carbohydrate Response Element Binding Protein (ChREBP), with antisense drugs. These exciting targets are also difficult to selectively inhibit with small molecules. The presentations further exemplify the versatility of the antisense approach for drug discovery and development.
Finally, Isis scientists presented data showing robust glucose lowering effects after reduction of the expression of renal sodium glucose transporter 2 (SGLT2) with an antisense drug optimized to target the kidney. The drug was extremely potent in inhibiting the target and caused greater than 80% reduction in SGLT2 expression at a dose less than 2 mg/kg/week, demonstrating about a 30-fold increase in potency compared to the standard phosphorothioate ASOs. This decrease in SGLT2 expression was accompanied by significant glucose lowering in several severely diabetic animal models including ob/ob and db/db mice.
ABOUT ISIS PHARMACEUTICALS, INC.
Isis Pharmaceuticals, Inc. is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners. The Company has successfully commercialized the world's first antisense drug and has 11 antisense drugs in development to treat metabolic, cardiovascular and inflammatory diseases, and cancer. In its Ibis division, Isis is developing and commercializing the TIGER biosensor system, a system that has the potential to revolutionize the identification of infectious organisms. As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of more than 1,500 issued patents worldwide. Additional information about Isis is available at http://www.isispharm.com.
This press release includes forward-looking statements regarding the development, therapeutic potential and safety of Isis' antisense drugs and in the treatment of metabolic diseases. Any statement describing our goals, expectations, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement, including those statements that are described as Isis' goals. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing, and commercializing drugs that are safe and effective for use as human therapeutics and in the endeavor of building a business around such products. Our forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause our results to differ materially from those expressed or implied by such forward-looking statements. Although our forward-looking statements reflect the good faith judgment of our management, these statements are based only on facts and factors currently known by us. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Isis' programs are described in additional detail on Form 10-K for the year ended December 31, 2004, and quarterly report on Form 10-Q for the quarter ended March 31, 2005, which are on file with the SEC. Copies of these and other documents are available from the Company.
Isis Pharmaceuticals, Inc.
Web site: http://www.isispharm.com/